Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "Peptide"

123 News Found

Biosynth Carbosynth expands peptide offering with acquisition of Pepscan
News | July 01, 2022

Biosynth Carbosynth expands peptide offering with acquisition of Pepscan

Addition of Pepscan with its peptide discovery, lead optimization and GMP manufacturing capabilities provides end-to-end offering to Biosynth Carbosynth’s peptide customers.


CPC Scientific announces new California peptide API manufacturing facility
News | June 24, 2022

CPC Scientific announces new California peptide API manufacturing facility

The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity


Iktos and Zealand Pharma to develop AI technology for peptide drug design
Digitisation | June 22, 2022

Iktos and Zealand Pharma to develop AI technology for peptide drug design

Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design


Gan & Lee gets U.S. FDA clearance for novel glucagon-like peptide-1 analogue
Biotech | December 07, 2021

Gan & Lee gets U.S. FDA clearance for novel glucagon-like peptide-1 analogue

The investigational compound, GZR18, is a novel analogue of glucagon-like peptide-1 (GLP-1), an incretin hormone responsible for many glucoregulatory effects


Piramal Enterprises forays into peptide with Hemmo Pharma : ICICI Securities
News | April 05, 2021

Piramal Enterprises forays into peptide with Hemmo Pharma : ICICI Securities

ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E


Syngene reports Q1 FY26 revenue higher at Rs. 875 Cr
News | July 23, 2025

Syngene reports Q1 FY26 revenue higher at Rs. 875 Cr

Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%


AstraZeneca plans to invest $50 billion in US by 2030
News | July 22, 2025

AstraZeneca plans to invest $50 billion in US by 2030

Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US


Bachem expands multi-site production capacities to meet rising demand
News | June 25, 2025

Bachem expands multi-site production capacities to meet rising demand

The Swiss peptide and oligonucleotide manufacturers roll out major investments across site networks in US, UK and Switzerland


AbbVie announces new data demonstrating Atogepant achieves superiority in Phase 3 study
Diagnostic Center | June 21, 2025

AbbVie announces new data demonstrating Atogepant achieves superiority in Phase 3 study

TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month


Sai Life Sciences FY25 PAT higher by 105% to Rs. 170 Cr
News | May 14, 2025

Sai Life Sciences FY25 PAT higher by 105% to Rs. 170 Cr

PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%